Prof. Igor F. Tsigelny is a Research Professor at the Department of Neurosciences, University of California, San Diego (UCSD). He is a world-known expert in structural biology, molecular modeling, bioinformatics, and structure-based drug design. He has a Ph.D. in Physics of Polymers from the Academy of Sciences of Ukraine. He was a postdoctoral fellow at the University of California in the laboratory of Susan S. Taylor. He is a member of the editorial boards of over 10 scientific journals. He has around 15 existing and pending patents. Two drug candidates developed by Prof. Tsigelny for the treatment of Parkinson’s disease and brain cancer are licensed by UCSD to pharmaceutical companies and are in various stages of development. His computational study of molecular mechanisms of Parkinson’s disease has been included in the US Department of Energy publication “Decade of Discovery”, where the best computational studies of the first decade of the XXI century have been described. He co-founded two companies: Neuropore-related to the development of drugs against Parkinson's disease, and CureMatch-devoted to personalized cancer medicine.
Research Keywords & Expertise
artificial intelligenc...
Bioinformatics
Structural Biology
Machine Learning (Ml)
Personalized drug trea...
Deep learning (DL)
Fingerprints
20%
Machine Learning (Ml)
5%
artificial intelligence
5%
Deep learning (DL)
5%
Bioinformatics
Short Biography
Prof. Igor F. Tsigelny is a Research Professor at the Department of Neurosciences, University of California, San Diego (UCSD). He is a world-known expert in structural biology, molecular modeling, bioinformatics, and structure-based drug design. He has a Ph.D. in Physics of Polymers from the Academy of Sciences of Ukraine. He was a postdoctoral fellow at the University of California in the laboratory of Susan S. Taylor. He is a member of the editorial boards of over 10 scientific journals. He has around 15 existing and pending patents. Two drug candidates developed by Prof. Tsigelny for the treatment of Parkinson’s disease and brain cancer are licensed by UCSD to pharmaceutical companies and are in various stages of development. His computational study of molecular mechanisms of Parkinson’s disease has been included in the US Department of Energy publication “Decade of Discovery”, where the best computational studies of the first decade of the XXI century have been described. He co-founded two companies: Neuropore-related to the development of drugs against Parkinson's disease, and CureMatch-devoted to personalized cancer medicine.
Advance your academic career, collaborate globally, and expand your network—
join now
!
Well done!
